Patients with bladder urothelial carcinoma were divided into four groups according to the mutations in SYNE2 and TP53. There were 48 patients with mutations in SYNE2 and TP53, 88 patients with mutations in SYNE2, 150 patients with mutations in TP53, and 184 patients with wild-type versions of both genes (Figure 6a). The gene discussed is TP53; the disease is bladder transitional cell carcinoma.